Thursday, 27 October 2016

Sun Pharma’s arm launches AG Versions for different Tablets

Leading pharma major, Sun Pharmaceutical Industries Ltd. has said that its wholly owned subsidiary has launched in US, the Authorized Generic (AG) versions for all strengths of Olmesartan Medoxomil tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Benicar (olmesartan medoxomil) tablets; Olmesartan Medoxomil-Hydrochlorothiazide tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Benicar HCT (olmesartan medoxomil-hydrochlorothiazide) tablets; Amlodipine Besylate-Olmesartan Medoxomil tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Azor (amlodipine and olmesartan medoxomil) tablets; and Amlodipine Besylate-Hydrochlorothiazide-Olmesartan Medoxomil tablets – therapeutic equivalent of Daiichi Sankyo Inc.’s Tribenzor (olmesartan medoxomil, amlodipine, hydrochlorothiazide) tablets.

For news on Indian Stock Market Tips,Mcx Commodity Trading Tips please visit us athttp://ripplesadvisory.com/free-trial.php or call at 9303093093.

The launch is pursuant to a distribution and supply agreement between Sun Pharma’s wholly owned subsidiary and Daiichi Sankyo Inc., which grants the Sun Pharma subsidiary, exclusive rights to distribute these tablets in the US for a pre-determined period. Benicar, Benicar HCT, Azor and Tribenzor recorded US sales of approximately USD 2.5 billion for the 12 months ending August 31, 2016, as per IMS Health.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.